Fixed ratio combinations GLP-1RA and basal insulin: literature review-Reference-Cited by-同舟云学术

Fixed ratio combinations GLP-1RA and basal insulin: literature review

Published:2024-02-28 Issue:1 Volume:70 Page:91-99
ISSN:2308-1430
Container-title:Problems of Endocrinology
language:
Short-container-title:Probl Endokrinol (Mosk)

Author:

Kurkin D. V.¹^ORCID,Bakulin D. A.²^ORCID,Morkovin E. I.³^ORCID,Strygin A. V.³^ORCID,Gorbunova Ju. V.²^ORCID,Volotova E. V.³^ORCID,Robertus A. I.²^ORCID,Makarenko I. E.⁴^ORCID,Saparova V. B.⁴^ORCID,Drai R. V.⁵^ORCID,Petrov V. I.³^ORCID

Affiliation:

1. Russian University of Medicine; Volgograd State Medical University

2. Russian University of Medicine

3. Volgograd State Medical University

4. Russian University of Medicine; CJSC «Farm-Holding»

5. CJSC «Farm-Holding»

Abstract

The progressive nature of type 2 diabetes mellitus leads to the need for insulin therapy in a significant proportion of patients. Very often start of insulin therapy in type 2 diabetes mellitus (T2DM) is associated with weight gain and a significant increase of hypoglycemia’s risk. However, innovative options, such as fixed ratio combinations of glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin, minimize weight gain and hypoglycemia risks and allow a greater proportion of patients to achieve individual glycemic control goals without compromising safety parameters. This review includes a description of the randomized clinical trials, as well as the results of real clinical practice of the use of two currently existing fixed ration combinations of GLP-1RA and basal insulin — iDegLira and iGlarLixi.

Publisher

Endocrinology Research Centre

Reference43 articles.

1. Kahn SE. The importance of b-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058. doi: https://doi.org/10.1210/jcem.86.9.7713

2. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV, Mayorov AY (11th edition). Diabetes mellitus. 2023;26(2S):1-231. (In Russ.). doi: https://doi.org/10.14341/DM13042

3. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi: https://doi.org/10.2337/dci22-0034

4. Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155-1164. doi: https://doi.org/10.1111/dom.12927

5. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417. doi: https://doi.org/10.2337/dc13-0331